000			03169nam a22004695i 4500
001			978-1-4614-0140-7
003			DE-He213
005			20140220083238.0
007			cr nn 008mamaa
008			111007s2012 xxu| s |||| 0|eng d
020			_a9781461401407 _9978-1-4614-0140-7
024	7		_a10.1007/978-1-4614-0140-7 _2doi
050		4	_aRC261-271
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a614.5999 _223
100	1		_aHarrington, David. _eeditor.
245	1	0	_aDesigns for Clinical Trials _h[electronic resource] : _bPerspectives on Current Issues / _cedited by David Harrington.
250			_a1.
264		1	_aNew York, NY : _bSpringer New York, _c2012.
300			_aXIV, 206 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aApplied Bioinformatics and Biostatistics in Cancer Research
505	0		_aNew designs for phase I dose finding studies -- Phase II/III designs for trials -- Design issues for clinical studies with genomic measurements -- Designing studies with longitudinal measurements subject to dropout -- Issues in sample size re-estimation -- Adaptive designs -- The design of non-inferiority trials -- Issues in the design of HIV prevention trials -- Randomization algorithms -- Sequential designs for phase III studies -- Case studies of difficult designs -- Ethical issues in the design of trials -- Index.
520			_aStatistical methods for clinical trials have been an area of active research in Biostatistics since the first modern clinical trials were mounted in 1946 by the British Medical Research Council in whooping cough and tuberculosis.  Often, the participants in clinical trials suffer from potentially fatal chronic diseases, and it is especially important that these experiments in medical research use designs that are efficient, can be understood by physicians, policy makers and patients, respond quickly new ideas in medicine and statistics, and, perhaps above all, show respect for the complex and important ethical issues that arise in these settings.   This book explores some recent thinking in designs for clinical trials, including alternative designs for phase I studies, interim monitoring for futility, adaptive designs based on accumulating outcome data, and designs of new, targeted therapies.  The book is intended for both the statistical practitioner, who may be too busy to stay abreast of the literature on statistical methods, as well as statisticians conducting research in clinical trials.
650		0	_aMedicine.
650		0	_aOncology.
650		0	_aToxicology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aPharmacology/Toxicology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781461401391
830		0	_aApplied Bioinformatics and Biostatistics in Cancer Research
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-4614-0140-7
912			_aZDB-2-SBL
999			_c100808 _d100808